« Back
Home /
Decernotinib

Decernotinib

Item no.	HY-12469-2mg
Manufacturer	MedChem Express
CASRN	944842-54-0
Amount	2 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 2 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.71
Citations	[1]Mahajan S, et al. VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 Mar 11. pii: jpet.114.221176.
Smiles	C[C@](C(NCC(F)(F)F)=O)(CC)NC1=NC(C2=CNC3=NC=CC=C32)=NC=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	VX-509; VRT-831509
Available
Product Description	Decernotinib is a potent, orally active JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.
StorageTemperature	4°C (Powder, protect from light, stored under nitrogen)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	392.38
Clinical Information	Phase 3
Manufacturers Research Area	Inflammation/Immunology
Solubility	DMSO : ≥ 50 mg/mL
Target	JAK
Manufacturers Target	JAK
Isoform	JAK1; JAK2; JAK3; Tyk2
Manufacturers Pathway	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12469-2mg-safety-datasheet.pdf